Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 30, 2017

DrugPatentWatch Database Preview

GLIPIZIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Glipizide, and when can generic versions of Glipizide launch?

Glipizide is a drug marketed by Sandoz, Barr Labs Inc, Unique Pharm Labs, Sun Pharm Inds Inc, Watson Labs, Mylan, Accord Hlthcare, Par Pharm, Vintage Pharms Llc, Ani Pharms Inc, Apotex, Mylan Pharms Inc, Zydus Pharms Usa Inc, Corepharma, Heritage Pharms Inc, and Teva Pharms. and is included in twenty-three NDAs.

The generic ingredient in GLIPIZIDE is glipizide; metformin hydrochloride. There are eighteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the glipizide; metformin hydrochloride profile page.

Summary for Tradename: GLIPIZIDE

Suppliers / Packagers: see list54
Bulk Api Vendors: see list72
Clinical Trials: see list14
Patent Applications: see list5,642
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GLIPIZIDE at DailyMed

Pharmacology for Tradename: GLIPIZIDE

Ingredient-typeSulfonylurea Compounds
Drug ClassSulfonylurea
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
glipizide; metformin hydrochloride
TABLET;ORAL077507-001Oct 27, 2005ABRXNoNo► Subscribe► Subscribe
TABLET;ORAL075795-002Jun 13, 2001ABRXNoNo► Subscribe► Subscribe
Heritage Pharms Inc
glipizide; metformin hydrochloride
TABLET;ORAL078728-003Jun 23, 2010ABRXNoNo► Subscribe► Subscribe
Sun Pharm Inds Inc
glipizide; metformin hydrochloride
TABLET;ORAL077620-002Jan 11, 2008ABRXNoNo► Subscribe► Subscribe
Teva Pharms
glipizide; metformin hydrochloride
TABLET;ORAL077270-001Oct 28, 2005ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Identify first generic entrants
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus